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Abstract 
 
Recent randomised trials on screening with low-dose computerised tomography (CT) have shown 
important reductions in lung cancer (LC) mortality and have triggered international efforts to 
implement LC screening. Detection rates of stage I LC with volume CT approaching 70% have been 
demonstrated. 
In April 2019 “ESMO Open – Cancer Horizons” convened a roundtable discussion on the challenges 
and potential solutions regarding the implementation of LC screening in Europe. The expert panel 
reviewed the current evidence for LC screening with low dose CT and discussed next steps which are 
covered in this article. The panel concluded that national health policy groups in Europe should start 
to implement CT screening as adequate evidence is available.  It was recognised that there are 
opportunities to improve the screening process through ‘Implementation Research Programmes’. 
 
 
Introduction 
 
Recent large randomised trials on low-dose computerised tomography (CT) screening including the 
American National Cancer Institute (NCI)-sponsored National Lung Screening Trial (NLST) as well as 
the Dutch/Belgian NELSON (Nederlands-Leuvens Longkanker Screenings Onderzoek) trial have 
shown significant reductions in LC mortality of 20-26% and have triggered international efforts to 
implement LC screening (1-3) . As demonstrated by results from the International Early LC Action 
Project (I-ELCAP) and the NELSON clinical trials groups, detection rates of stage I LC with volume CT 
could approach 70%.  
In April 2019 “ESMO Open – Cancer Horizons” convened a roundtable discussion on the challenges 
and potential solutions regarding the implementation of LC screening in Europe. The expert panel 
reviewed the current evidence for LC screening with low dose CT and discussed next steps which are 
covered in this article. 
 
Figure 1 shows levels of evidence for implementation of LC screening in Europe.  
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Figure 1: Levels of evidence for implementation of LC screening in Europe (4) 
 
 
Amended/updated in 2019 from a figure published in (4) in 2016. 
Colour codes: green: sufficient evidence; amber: borderline evidence 
Abbreviations: CT, computerised tomography; UKLS, United Kingdom Lung Cancer Screening Trial; NELSON, 
Nederlands-Leuvens Longkanker Screenings Onderzoek ;NLST, National Lung Screening Trial ; QALY, quality-
adjusted life year; MDT, multi-disciplinary team; NICE, national institute for health and care excellence; LDCT, 
low dose CT; VDT, volume doubling time; LLP, Liverpool Lung Project; PLCO, Prostate, Lung, Colorectal and 
Ovarian Cancer Screening Trial. 
 
 
 
 
Recruitment for national LC screening programmes 
 
The aim regarding recruitment for national LC screening programmes is to achieve an informed 
participation focusing on high-risk (hard-to-reach) individuals. Those at highest risk of lung cancer 
are those who are most likely to benefit from screening (even when considering co-morbidity); 
however, they are less likely to participate in LC screening and are more likely to be of lower 
socioeconomic background and to be current smokers (4) .  
 
Recruitment challenges 
 
Screening approaches 
It is a difficult balance between the availability of systematic risk data of a relatively large group of 
approachable individuals (health registers, primary care registers, questionnaires, online surveys) 
and ensuring equity: versus the less systematic and less costly approaches for smaller groups, which 
are likely to be the worried-well (through clinics and advertising).  
 
Age 
It has been argued whether to start recruitment at age 60 or 55.  Screening strategies for 
Switzerland indicate a starting age of 60, and include those up to 79 years of age. The National 
 6 
Health Service (NHS) England Protocol (5) however argues for screening between 55 to 75 years of 
age. A number of risk prediction models have been developed, of which the Prostate, Lung, 
Colorectal and Ovarian Cancer Screening Trial (PLCO)2012 (6) (1.6% risk over 6 years) and the 
Liverpool Lung Project (LLP)v2 (7, 8) ( 2.5% risk over 5 years) have both been included in the recent 
NHS England Protocol.  
In the United States of America (USA), the  United States Preventive Services Task Force (USPSTF) (9) 
on LC screening has a much less stringent selection criteria, which is based on the NLST trial and the 
Cancer Intervention and Surveillance Modelling Network (CISNET) modelling (10). 
 
Smoking 
Some consider one basic inclusion question would suffice “have you ever smoked?“ . 
 
Information technology 
Investment into information technology systems are needed to collate patients’ risk data and also to 
manage and monitor LC CT screened patients. In the UK this has recently been amplified by Sir 
Professor Richard’s Interim Report on UK Cancer screening (11).  
 
 
Role-out of LC in Europe 
 
The roundtable panel recognised that LC screening can be initiated in Europe, however there is room 
for improvement in several areas and the recommendation discussed, is provided in Figure 2.  
 
Figure 2: European implementation trials needed  
 
Source: private communication de Koning and van der Aalst 
 
LC screening 
 
(i) Radiology protocol 
 
The most recent European protocol of the management of CT detected nodules was published in the 
Lancet Oncology 2017 (3) which was developed as a consensus document by experts from nine 
countries within Europe. Using volume doubling time (VDT) biomarker reduces invasive procedures, 
biopsies and surgery by tenfold (12) compared to the NLST data (1). 
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Recently, it has been recognised that new nodules are common in follow-up CT scans (3-13% 
screenings) (13) (14) and comprise a significantly higher LC probability, which are at smaller size, 
thus the recommendation for new nodules during the screening process 
This more stringent cut-off values should be mandatory: 
• Negative screen result: <30mm3 (LC probability <1%) 
• Indeterminate screen result: 30-200mm3 (LC prob ~3%) 
• Positive screen result: >200mm3 (LC prob ~17%). 
 
(i) Screening interval  
The screening interval, annual versus biennial, has been debated in the literature (15-17), however, 
clearly the optimal screen intervals should consider using the previous CT screen results to estimate 
LC risk. However, in the light of the recent NELSON results given at the World Conference on Lung 
Cancer (WCLC) 2018 (2), the annual screening frequency is considered the default until more data 
supporting other approaches may be available. However, it is recognised that there is a potential 
avenue to select individuals with a low risk of developing lung cancer utilising their base line scan 
and depending on their overall risk  profile, could be considered for biennale screening (18-20), this 
would need continues monitoring during the screening lifetime of the patient.  
 
 
(ii) Quality assurance 
Quality assurance (QA) in CT screening has been poorly implemented. Therefore, the prospect of 
setting up LC CT Screening Imaging Core laboratories for QA as well as benchmarking the automated 
CT scan software and post-processing procedures are attractive options. However mature, validated 
tools for these purposes are not yet widely available. In the meantime, there is a preference for the 
delivery of LC screening care in dedicated clinical centres of excellence and using virtual central 
reading of the CT scans. 
 
(iii) Mortality reduction in women 
The NELSON presentation at WCLC 2018 provides evidence for lung cancer mortality reduction in 
women (39-61%)  (2, 21). In the NLST this figure was 27%  for women (Figure 3).  The implication for 
the higher mortality gain in women compared to men is poorly understood and requires further 
investigation. 
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Figure 3: LC CT screening: NLST and NELSON Mortality data presented at the WCLC 2018 
 
Source: data provided by de Koning H. at WCLC 2018 (2, 21) 
 
 
(iv) Prolonged low dose CT screening 
The Multicentric Italian Lung Detection (MILD) trial recently evaluated the benefit of prolonged low 
dose CT screening beyond 5 years, and its impact on overall and LC specific mortality at 10 years 
(22). MILD prospectively randomised 4099 participants, to a screening arm (n ¼ 2376), with further 
randomization to annual (n ¼ 1190) or biennial (n ¼ 1186) low dose CT for a median period of 6 
years, or control arm (n ¼ 1723) without intervention.  
In the MILD trial, 2005 and 2018, 39 293 person-years of follow-up were accumulated. The primary 
outcomes were 10-year overall and LC specific mortality.  The low dose CT arm showed a 39% 
reduced risk of LC mortality at 10 years [hazard ratio (HR) 0.61; 95% confidence interval (CI) 0.39–
0.95], compared with control arm, and a 20% reduction of overall mortality (HR 0.80; 95% CI 0.62–
1.03). The MILD trial provides further evidence that prolonged screening beyond 5 years can 
enhance the benefit of early detection and achieve a greater overall and LC mortality reduction 
compared with NLST trial. 
 
 
Secondary Care pathways: UK protocols to assist the implementation of LC screening 
 
The UK national optimal LC pathway (NOLCP) is a timed secondary care pathway approved by NHS 
England. (Figure 4) 
 
Key features of the early part of the NOLCP include recommendations for rapid access to a CT thorax 
(within 72h of referral or chest radiograph) and a subsequent triage process. The latter stratifies 
patients with suspicious CT findings into fast track cancer clinics, with subsequent rapid investigations 
for and management of LC, or appropriately diverts others from cancer pathways into alternative 
services. This includes the management of pulmonary nodules according to the British Thoracic 
Society guideline (23).  
 
Figure 4: National Optimal LC Pathway for suspected and confirmed LC: Referral to treatment UPDATE 
2017 v2 produced by the Clinical Expert Group for Lung Cancer, NHSE. 
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The integration of the NOLCP with CT screening provides an opportunity to transform care.  As it 
maximizes the benefits of each and ensures that optimal care is provided to patients throughout their 
clinical pathway. The current UK cancer waiting times and unwarranted variations in care reflect 
systemic problems in organisational process and capacity. Thus, this must be driven nationally with 
regional and local coordination of funding and services. 
 
 
Multidisciplinary clinics: planning for long-term treatment of CT screened LC patients with a 
diagnosis of cancer 
 
It is important that medical oncologists are part of the long-term treatment planning of CT screened 
patients with a diagnosis of LC; the same is true for radiologists, pulmonologists, surgeons, nuclear 
medicine physicians and cancer nurses.  A critical member of the team is the smoking cessation 
counsellor as the enhanced feedback associated with annual attention to smoking cessation seems 
to enhance quit rates. The cost of medical care in older smokers can be significantly reduced (by 
about one third) by inclusion of best practice smoking cessation advice (24-26) and greatly enhance 
the cost utility of this integrated screening service. 
 
Large scale implementation of LC screening within nationwide screening programmes in Europe will 
significantly change the landscape of treatment strategies for patients due to earlier diagnosis. 
Hopefully, less patients with advanced stages will need more palliative approaches with systemic 
treatment (chemotherapy, chemo-immunotherapy, immunotherapy) but more patients may need 
adjuvant and consolidation systemic treatments (stages II, III, chemotherapy, immunotherapy). 
Furthermore, conversations should also be starting on how to use best practice guidelines to 
manage the large number of asymptomatic screening subjects who will be found to have objective 
evidence of chronic obstructive pulmonary disease (COPD) or advanced coronary calcifications. 
Important trials in the Netherlands (25) and China are already exploring this critical new avenue of 
public health investigation. 
 
Medical oncologists may also need to shift their interest from the approaches to advanced disease to 
‘multidisciplinary approaches’ of stages II, IIIA, IIIB, and IVA of LC. Further clinical trials with systemic 
treatments for very early LC stages (immunotherapy, chemo-immunotherapy, targeted therapy) can 
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be foreseen. As new cancer precursors are detected within the screening population, a new 
generation of chemoprevention trials can be expected. This could potentially include immunological 
manipulation of the early cancer development process.  
 
 
LC biomarkers in early LC detection 
 
The ‘holy grail’ in biomarker research is to identify other early detection biomarker(s) beyond the 
above discussed imaging biomarkers.  Despite a massive investment of resources, non-imaging 
biomarkers have had limited success.  A recent systematic review on serum and blood based 
biomarkers for LC screening provided an excellent update of this topic (27). It evaluated the 
diagnostic performance of Early CDT-lung (an antibody based biomarker screening panel), micro- 
ribonucleic acid (RNA) signature classifier (MSC, a plasma-based 24 miRNA risk score), and miR-test 
(a serum-based 13 miRNA signature), and their impact on LC-related mortality and all-cause 
mortality. Three phase III studies were identified, and all three biomarker assays show promise for 
the detection of LC. However, there was a lack of definitive evidence to justify integration into 
clinical practice. 
 
Seijo and colleagues (28) have recently proposed a number of principles to optimize LC biomarker 
discovery projects. They provided an overview of promising molecular candidates, such as 
autoantibodies, complement fragments, microRNAs, circulating tumor deoxyribonucleic acid (DNA), 
DNA methylation, blood protein profiling, and RNA airway or nasal signatures. The emerging 
biomarkers, including exhaled breath biomarkers, metabolomics, sputum cell imaging, genetic 
predisposition studies, and the integration of next-generation sequencing into study of circulating 
DNA. All of these need to be considered in the scope of future implementation research in LC 
screening, together with imaging, radiomics, and artificial intelligence (29).   
 
 
Recent innovative research programmes: which can impact on future LC screening implementation 
research. 
 
-Early Lung Imaging Confederation (ELIC) 
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Since the global implementation of LC screening is only starting just now, there has not been the 
time nor the resources so far to create specialised imaging tools to enable easy and rapid LC 
screening management. The Quantitative Imaging Biomarker Alliance (QIBA) organised by the 
Radiological Society of North America (RSNA) has been working to define scalable solutions to insure 
robust and accurate use of volumetric CT imaging to guide screening work-up (30), as already 
published in the UKLS (8) and NELSON trials (3). Large collections of thoracic CT images with known 
clinical outcomes  are urgently needed to develop and validate LC imaging management tools (31).  
 
IASLC is committed to developing a large collection of thoracic CT images to address this bottleneck 
(32). IASLC with a large multi-disciplinary team has begun to develop the Early Lung Imaging 
Confederation (ELIC).  The goal is to make this cloud-based image collection/ research resource 
accessible to all IASLC investigators as well as others, as an open resource to accelerate the 
development of imaging and other tools to manage early LC.  
 
-Institute of Diagnostic Accuracy Management System (iDNA)  
 
The iDNA Management System has been developed from the NELSON and UKLS screening trial 
databases (8, 12). It is a highly configurable client tracking system where clients are screening 
participants (or patients), and where all types of events are stored in the client’s history. This client 
history contains all relevant details needed for logistical and data management, including features 
specifically designed for LC screening purposes such as nodule evaluation across multiple 
evaluations and across multiple scan moments. This allows central review of CT scans, automated 
calculations on VDTs and automated classification of screening results (based on the optimized 
NELSON protocol). Secondly, the software is designed to support clear and secure communication 
between the screening site and the screening participants on undertaking LC risk assessment (LLPv2 
and PLCO2012), making appointments, completion of questionnaires (e.g. on smoking history, and 
informed consent), reporting on screening results, integration with e-mail and the use of 
configurable templates for standard notifications and letters. With the iDNA Management System all 
the screening sites’ specific needs on data collection, logistics and communication can be configured 
by local administrators, ensuring full compliance with local requirements.  
Collection of radiological metadata is organised in multiple steps and levels which is based on a 
direct link between the radiologist’s workstation and the iDNA management system: a screening 
participant can have more than one CT scan record; one CT scan record can have multiple 
readings/observations and one observation can have multiple nodules and other findings.  
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The primary application of the iDNA Management system is the registration and management of 
nodules in LC screening programmes. The iDNA system has been extended with registration and 
management of calcium scores (for cardiovascular diseases) (33)30)  which can be utilised by 
collaborative screening sites  (34). Other radiological features include the validated import of 
eXtensible Markup Language (XML) files generated by local workstations directly into the study 
database. 
Other comparable systems are being developed including a collaborative effort between the 
Veterans Administration in the United States working with the International Early LC Action Project 
with support from the Bristol Myers Squibb Foundation using an open-source software environment.  
 
GDPR 
 
The recommendation of  a European registry for collection of LC CT screening data was discussed at 
the roundtable and that the International Association for the Study of Lung Cancer (IASLC) is 
exploring options in this regard (32). Ideally a registry for screened LC CT images should be 
developed. However, the changing laws around the EU General Data Protection Regulation (GDPR) 
are making this more difficult as it is practically impossible to anonymise CT Digital Imaging and 
Communications in Medicine (DICOM) images. This is a challenge not just within the LC community, 
it impacts on all radiological imaging and needs to be resolved within the European Parliament. It 
would be tragic if reasonable measures to ensure personal data protections were to unintentionally 
delay or even block progress in improving curative outcomes for Europe’s most lethal adult cancer. 
 
 
 
Conclusion 
The conclusion reached by the roundtable panel was that national health policy groups in Europe 
should start to implement CT screening now as adequate evidence is available (4, and figure 1).  It 
was recognised that there are opportunities to improve the ‘screening process’ through 
‘Implementation Research Programmes’. Areas which need specific consideration are around cost 
effectiveness (UKLS data indicates £12,000/ quality-adjusted life year (QALY)) and if biennal 
screening is appropriate for a subset of individuals with appropriately delivered integrated smoking 
cessation programmes in place. 
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Overall recommendations: 
 
1. Implementation of LC screening should be a priority in Europe. It this needs to be driven 
scientifically, politically and also utilising patient advocacy. 
2. Europe needs to plan ‘Implementation Research Programmes’. 
3. Investment is needed into recruitment challenges especially in ‘hard to reach’ communities. 
4. Ensure thoracic radiologists reporting on CT screened individuals utilise volume and VDT and 
are provided with the necessary training and work with quality assurance procedures are in 
place. 
5. The issues around current GDPR need to be resolved, in order to enable the development of 
a European registry for collection of LC CT screening data. 
6. Secondary Care Pathways are aligned with the imminent implementation of LC screening, 
together with service provision and availability of screening platforms. 
7. Develop a collegiate approach to the work-up and treatment of LC patients in multi-
disciplinary clinics, identified through CT screening programmes. All clinical specialties 
should be fully engaged, including medical oncologists. 
8. The role of non-imaging early detection biomarkers is still in an early phase; however, the LC 
screening community should be fully engaged and participate in the developing integrated 
research programmes utilising molecular / radiomics and AI approaches. 
9. Innovative research programmes (e.g. ELIC and iDNA) provide enormous potential which can 
impact on LC screening and save lives. 
10. LC CT screening will happen in Europe. It is up to the community to make it happen now. 
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